Status:
COMPLETED
Staccato Loxapine Pulmonary Safety in Healthy Volunteers
Lead Sponsor:
Alexza Pharmaceuticals, Inc.
Conditions:
Healthy
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
The objective of this trial is to assess the pulmonary safety of 2 inhaled doses of Staccato Loxapine within a day.
Detailed Description
The planned study is a multiple dose, double-blind, placebo-controlled, randomized, 2-sequence, 2-period crossover study investigating pulmonary safety in healthy volunteers.
Eligibility Criteria
Inclusion
- nonsmoker subjects in good general health with normal spirometry at screening AND baseline
Exclusion
- history of asthma, COPD, or any other acute or chronic pulmonary disease or bronchodilator use
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2009
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00789360
Start Date
November 1 2008
End Date
April 1 2009
Last Update
March 11 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Northeast Medical Research
North Dartmouth, Massachusetts, United States, 02747